BACKGROUND:N-terminal pro-B-type natriuretic peptide (NT-proBNP) is an established marker of myocardial stress, yet its prognostic role in tricuspid valve transcatheter edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR) remains unclear. OBJECTIVES:The aim of this study was to evaluate the prognostic value of baseline NT-proBNP and its early postprocedural trajectory after T-TEER. METHODS:Patients undergoing T-TEER with available baseline NT-proBNP measurements in the EuroTR (European Registry of Transcatheter Repair for Tricuspid Regurgitation) registry were analyzed. NT-proBNP was evaluated continuously and by tertiles, with longitudinal changes assessed when serial measurements were available. Endpoints were the 2-year composite of all-cause mortality or first heart failure hospitalization, changes in NT-proBNP, symptomatic alleviation, and residual TR. RESULTS:In total, 2,282 patients (median age 80 years [Q1-Q3: 76-83 years], 54% women, 86% in NYHA functional class III or IV) with baseline NT-proBNP values (tertile 1, ≤1,674 pg/mL; tertile 2, 1,674-3,743 pg/mL; and tertile 3, >3,743 pg/mL) were included. Higher tertiles were associated with greater comorbidity burden, more advanced biventricular remodeling, and more severe TR. Baseline NT-proBNP was independently associated with the primary endpoint (adjusted HR: 1.62; 95% CI: 1.29-2.04). Residual TR ≤2+ at discharge occurred in 86.3%, 82.9%, and 81.4% across tertiles (P = 0.040), and higher NT-proBNP was associated with a lower likelihood of symptomatic alleviation (adjusted OR per log10 increase: 0.63; 95% CI: 0.48-0.84; P < 0.001). Both baseline NT-proBNP and higher than expected 30-day levels relative to baseline were independently associated with higher subsequent risk for the primary endpoint. CONCLUSIONS:Baseline NT-proBNP was independently associated with 2-year mortality or heart failure hospitalization after T-TEER. Early postprocedural NT-proBNP trajectories provided incremental prognostic information and may identify patients at increased risk.
INTRODUCTION:The impact of coexisting left-sided valvular heart disease (VHD) on clinical outcomes following tricuspid valve edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR) remains unclear, particularly under real-world conditions. To evaluate the prevalence and prognostic impact of concomitant left-sided VHD in patients undergoing T-TEER. METHODS:This study included all patients undergoing T-TEER from the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR; NCT06307262) with complete echocardiographic data on left-sided valve disease. Study endpoints included survival and heart failure hospitalizations (HFH) at 2 years, NYHA functional class, and TR reduction. RESULTS:Among a total of 1647 eligible patients, 95.8%, 35.6%, and 3.8% had ≥mild, moderate, and severe concomitant VHD, respectively. Moderate or higher VHD was associated with a significantly reduced 2-year survival (P < .001) and reduced 2-year HFH-free survival (P = .005). Multivariate regression analysis confirmed ≥ moderate VHD to be an independent predictor of mortality (hazard ratio 1.54, 95% CI 1.21-1.96, P < .001). Despite worse TR and NYHA functional class at baseline in patients with ≥moderate VHD, T-TEER was associated with a significant TR reduction (P < .001) and symptomatic improvement (P < .001). CONCLUSION:Concomitant left-sided VHD is common among patients undergoing T-TEER and is independently associated with worse survival and higher rates of HFH. Nevertheless, T-TEER provides meaningful symptomatic benefit and durable TR reduction in patients with and without VHD burden.
Abstract Objective The clinical significance of prior percutaneous coronary intervention (PCI) in patients undergoing coronary artery bypass grafting (CABG) remains debated, particularly regarding long-term mortality, need for repeat revascularization, and the prognostic value of intraoperative graft flow. Methods In this single-center retrospective cohort study, 3,591 patients who underwent isolated CABG between 2005 and 2023 were analyzed and stratified by prior PCI status. Baseline, surgical, and follow-up data were collected, with multivariable regression and interaction analyses performed to investigate associations between prior PCI, reintervention, mortality, and intraoperative graft flow. Results Prior PCI was not associated with increased mortality after adjustment for clinical and procedural variables (HR 1.00, 95%CI 0.861-1.160, p > 0.99), but independently predicted higher rates of repeat coronary reintervention (HR 1.553, 95%CI 1.225-1.969, p < 0.001), especially for recent and urgent PCI (HR 2.304, 95%CI 1.141-4.651, p = 0.020). The prognostic effect of prior PCI was heterogeneous, with adverse outcomes more closely associated in unfavourable coronary anatomy. Importantly, intraoperative graft flow to the right coronary artery was predictive for adverse events only in patients with prior PCI (Interaction p = 0.002; HR 0.424, 95%CI 0.244-0.738 per log2-increment in RCA graft flow within the prior-PCI stratum). Conclusion Prior PCI was not independently associated with increased mortality after CABG but is a predictor of repeat revascularization. The effect is heterogeneous and most pronounced among patients with additional risk factors and reduced right coronary graft flow. These findings underscore the need for individualized risk assessment and tailored perioperative management in CABG patients with a history of PCI.
Abstract Background Heart failure–related cardiogenic shock (HF-CS) is the leading etiological subtype of CS, accounting for more than 50% of cases in contemporary registries. Within this CS subset, the impact of out-of-hospital cardiac arrest (OHCA) on clinical trajectories and outcomes remains insufficiently characterized. Purpose The aim of this study was to evaluate clinical characteristics and outcomes in patients with HF-CS with and without OHCA. Methods Patients with HF-CS treated at 16 tertiary-care centers across five countries between 2011 and 2021 were analyzed. To evaluate differences in clinical characteristics, 30-day mortality, and in-hospital complications, patients with and without OHCA were compared using multivariable logistic and Cox regression models, adjusted for age and sex. Results Among 1,024 patients with HF-CS, 395 (38.6%) presented with OHCA. The median age was 64 years (interquartile range [IQR] 52–75), 289 (28.2%) were female. At admission, median lactate was 5.0 mmol/L (IQR 2.6–8.6), and the baseline left ventricular ejection fraction was 20% (IQR 15-30). Among patients with OHCA, 233 (59.0%) presented with previously known HF (acute-on-chronic HF-CS), whereas 162 (41.0%) had no prior history of HF (de novo HF-CS). Overall, a prior history of HF was inversely associated with OHCA (OR 0.52, 95% CI 0.39–0.68; p<0.001), whereas ischemic cardiomyopathy alone was independently associated with increased odds of OHCA (OR 1.83, 95% CI 1.27–2.62; p=0.001). Higher lactate levels upon admission were more frequently associated with OHCA (OR 2.41, 95% CI 1.96–2.98; p<0.001). Patients with HF-CS and OHCA had an approximately 10% higher absolute 30-day mortality compared with those without OHCA (57.2% vs. 47.4%; adjusted hazard ratio 1.62, 95% CI 1.34–1.95, p<0.001, Figure 1). Patients with OHCA more frequently experienced hypoxic brain injury compared with those without OHCA (17.3% vs. 1.0%, p<0.001). Other in hospital complications, including ischemic and bleeding events, stroke and sepsis, were comparable between groups. Conclusions In this multicenter observational study, OHCA appears to represent a substantial risk modifier in patients with HF-CS. These findings call for external validation.
Aims This multicenter study aims to compare outcomes of total aortic arch replacement (TAR) using the frozen elephant trunk (FET) technique in patients with and without heritable thoracic aortic disease (HTAD) and to assess whether HTAD influences postprocedural adverse aortic events (AAEs). Methods From 06/2007 to 05/2024, aortic databases from 13 European centers were screened for HTAD patients undergoing TAR with FET. All consecutive dissection and aneurysm non-HTAD patients from the four core centers served as comparator. The primary outcome was AAE, a composite of diameter progression, distal stent graft induced new entry (dSINE), malperfusion, rupture and pseudoaneurysm at 5 years after FET implantation. Results Of 2739 FET patients, 196 (7.2%) were diagnosed with HTAD. The control group consisted of 867 non-HTAD FET patients. Marfan syndrome was the most common condition (72%), followed by Loeys-Dietz syndrome (11%), vascular Ehlers-Danlos syndrome (5.6%) and Turner syndrome (2.0%). Seventeen (8.8%) patients were diagnosed with ns-HTAD. At 5 years 46 (24%) AAEs occurred in the HTAD group, 169 (20%) in the non-HTAD group (p=0.2). Diameter progression was the most common event (10% vs. 12%; p=0.6), followed by dSINE (5.8% vs. 4.5%; p=0.5), malperfusion (4.2% vs. 3.3%; p=0.5), rupture (2.1% vs. 0.7%; p=0.09) and pseudoaneurysm (0.5% vs. 0.2%; p=0.5). Conclusions The FET technique appears safe and effective for acute and chronic aortic disease in HTAD patients, with outcomes comparable to non-HTAD cases and no increase in graft-related complications, challenging traditional concerns about stent graft use in genetically mediated aortic disease. ### Competing Interest Statement Martin Czerny reports consultancy fees from Medira and NEOS, and consultancy for Terumo Aortic, Medtronic, and Endospan; a one-time direct personal payment (speaking honorarium) from Abbott; payment to their institution from Terumo aortic for postmarket registries for study nurses. Martin Czerny holds shares from TEVAR Ltd. and from Ascense Medical. Maximilian Kreibich reports direct personal payment (speaker honoraria) from Terumo Aortic. Sven Peterss reports serving as a consultant/proctor and receiving speaker honoraria and travel compensation from Artivion, Edwards Lifesciences Services, AstraZeneca, CytoSorbents, and Terumo Aortic. Maximilian Pichlmaier reports serving as a consultant/proctor for Terumo Aortic and Artivion. Martin Grabenwöger reports consultancy fees from Artivion. Daniel-Sebastian Dohle reports serving as a consultant for Artivion, Edwards, Medira, and VarmX. Maximilan Luehr reports speaker honoraria from Artivion EMEA Inc. Tomas Holubec reports receiving consulting, speaker honoraria and travel compensations from Abbott, USA; Artivion, USA; Edwards Lifesciences, USA; Getinge, Sweden and Smartcanula LLC, Switzerland. Jens Brickwedel reports serving as a consultant for receiving speaker honoraria and receives travel compensation from Terumo Aortic. Christian Detter reports serving as a consultant/proctor for and receives travel compensation from Terumo Aortic. Jörg Kempfert and Leonard Pitts have received educational grants, including travel support, fees for lectures and speeches, as well as for professional consultation and research from Artivion (Hechingen, Germany/Atlanta, GA, USA) and Terumo Aortic (Inchinnan, UK). The other authors have reported no competing interests. ### Clinical Trial It is a retrospective Study registered in Freiburg FRKS005257 ### Funding Statement Institutional funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRB approval for this multicenter study was obtained on 30/07/2024 (24-1247-S1-retro) from the Ethics Committee of the University of Freiburg and the need for individual informed consent was waived due to the retrospective design. Anonymous data sharing was approved at each individual participating center. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The datasets analyzed during the current study are not publicly available due to strict institutional and ethical restrictions regarding patient data protection and confidentiality and are therefore not available for sharing. Data are available from the corresponding author on reasonable request, subject to approval by the relevant institutional review boards and data-sharing agreements with participating centers.